Here are 1-2 brief analogies for Orchestra BioMed (OBIO), based on the provided background description of it as a SPAC:

1. It's like a publicly traded private equity firm whose sole mission is to acquire one private company and take it public.
2. Think of it as a publicly listed investment fund that specializes in finding and acquiring a single private company to bring to the stock market.

• Virtue® Sirolimus-Eluting Balloon (SEB): A drug-eluting balloon designed to prevent restenosis in patients with coronary and peripheral artery disease by delivering sirolimus to the vessel wall.
• BACKBEAT™ Cardiac Neuromodulation Therapy (CNT): A therapy platform under development that aims to reduce blood pressure in pacemaker patients by modulating the autonomic nervous system via specialized pacing.

David P. Hochman, Chairman, Chief Executive Officer and Founder

Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He is also the founder of Orchestra BioMed, Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies, and Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. With over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking, Mr. Hochman was a co-founder of PROLOR Biotech, Inc., which was acquired by Opko Health for over $600 million in 2013. He also served as a board advisor of Health Dialog Services Corporation, acquired in 2008 by the British United Provident Association for $750 million. Prior to Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies.

Andrew Taylor, Chief Financial Officer

Mr. Taylor was appointed Chief Financial Officer of Orchestra BioMed in June 2023. He brings over 20 years of CFO experience, with the last 15 years in the medical device sector. Previously, Mr. Taylor served as CFO of Motus GI Holdings, Inc., where he helped lead the company's 2018 IPO. He also spent 10 years as CFO and President of Avertix Medical, Inc. (formerly Angel Medical Systems, Inc.) and was CFO and Corporate Director of Operations for Safe3w, Inc. (acquired by iPass).

Darren R. Sherman, President, Chief Operating Officer and Founder

Mr. Sherman serves as President, Chief Operating Officer, and a Founder of Orchestra BioMed.

Bill Little, Executive Vice President, Corporate Development and Strategy

Mr. Little joined Orchestra BioMed in June 2023. Prior to joining Orchestra BioMed, he served as Chief Operating Officer at Neovasc, which was successfully acquired by Shockwave Medical in April 2023. He has 25 years of experience in the medical device industry, including leadership roles at Abbott Vascular, where he was Divisional Vice President of Global Marketing, and St. Jude Medical, where he served as Vice President of Global Cardiovascular Therapies.

Mark Pomeranz, Executive Vice President and General Manager, Interventional Therapies

Mr. Pomeranz joined Orchestra BioMed in November 2024, bringing over 35 years of experience in the medical device industry. He has a track record of commercializing more than 50 products. Prior to Orchestra BioMed, he was CEO of Motus GI and was the founding CEO of Svelte Medical Systems from 2007 to 2014, where he led the development of a drug-eluting stent platform. He also spent nearly a decade at Cordis, a Johnson & Johnson company, as Vice President.

1. Clinical Trial and Regulatory Approval Risks: As a company developing medical devices and therapies, Orchestra BioMed is subject to inherent risks associated with the success rates of clinical trials and the arduous process of obtaining regulatory approvals. The company's flagship product candidates, AVIM Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon (SAB) for atherosclerotic artery disease, are currently in clinical development. The failure of these trials or the inability to secure necessary regulatory approvals (e.g., FDA approval) would significantly impede the company's ability to commercialize its products and generate substantial revenue, making it a fundamentally speculative investment at this stage of development.
2. Financial Health and Profitability Challenges: Despite reporting some revenue increases, Orchestra BioMed has demonstrated ongoing challenges with profitability, exhibiting significant net losses and negative earnings per share. The company's net margin and operating margin are substantially negative, reflecting high operational costs, particularly in research and development due to ongoing pivotal studies. While the company has secured new capital and extended its cash runway, persistent unprofitability and significant cash burn raise concerns about its long-term financial stability and its ability to fund crucial clinical programs if substantial, sustainable revenues are not achieved.
3. High Stock Volatility: Orchestra BioMed's stock exhibits high volatility, with a beta of 1.9, indicating greater sensitivity to overall market movements. This high volatility suggests that the stock price can experience significant fluctuations, which may present a higher risk for investors.

Orchestra BioMed (OBIO) focuses on two primary product candidates with significant addressable markets:

• Atrioventricular Interval Modulation (AVIM) Therapy (also known as BackBeat Cardiac Neuromodulation Therapy): This therapy is designed for the treatment of hypertension. Orchestra BioMed estimates an addressable market of over 7.7 million patients in the U.S. who meet the criteria for Breakthrough Device Designation for AVIM therapy, specifically those with uncontrolled hypertension and increased cardiovascular risk who are indicated for a pacemaker. Additionally, the company estimates a worldwide annual market comprising at least 3.7 million patients with uncontrolled hypertension not yet indicated for a pacemaker but with high cardiovascular risk and co-morbidities, representing a potential annual revenue opportunity of over $15 billion.
• Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB): This product is for the treatment of atherosclerotic artery disease. Orchestra BioMed estimates the total global market opportunity for drug-eluting balloons, which includes Virtue SAB, to be over $10 billion annually. For context, the broader global angioplasty balloons market was valued at US$3 billion in 2023 and is projected to reach US$4.2 billion by the end of 2033, with the United States holding a 40% market share.

Here are 3-5 expected drivers of future revenue growth for Orchestra BioMed (OBIO) over the next 2-3 years:

1. Commercialization of BackBeat Cardiac Neuromodulation Therapy (AVIM Therapy) for Hypertension: Orchestra BioMed's flagship product candidate, BackBeat Cardiac Neuromodulation Therapy (CNT), also referred to as Atrioventricular Interval Modulation (AVIM) therapy, is designed to treat hypertension. The company is actively accelerating patient enrollment in the global pivotal BACKBEAT study in collaboration with Medtronic. The AVIM therapy has received FDA Breakthrough Device Designation, which could expedite its path through the regulatory approval process. With an estimated total addressable market of 750,000 patients worldwide annually and a potential revenue opportunity of $2 billion, successful completion of clinical trials and subsequent commercial launch of AVIM therapy are significant revenue drivers.
2. Commercialization of Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for Artery Disease: The Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a proprietary drug/device combination product, is another lead product candidate aimed at treating atherosclerotic artery disease. Orchestra BioMed has initiated patient enrollments in the Virtue SAB U.S. pivotal trial, comparing it to a commercially available paclitaxel-coated balloon. The company has also established a right of first refusal agreement with Terumo related to Virtue SAB for coronary artery disease, following a new agreement in late 2025 that significantly contributed to 2025 revenue. Future revenue growth is anticipated from the eventual commercialization and market penetration of Virtue SAB through this strategic partnership.
3. Expansion and Leveraging of Strategic Partnerships: Orchestra BioMed operates with a partnership-enabled business model, forging collaborations with market-leading global medical device companies to accelerate the commercialization of its products. These partnerships, such as those with Medtronic for AVIM Therapy and Terumo for Virtue SAB, are crucial for sharing development costs and gaining access to established commercial networks and customers globally. The company bolstered its financial position with approximately $150 million in new capital and commitments from strategic transactions with Medtronic, Ligand, and Terumo in the second half of 2025, which underscores the importance of these collaborations for funding and future revenue streams.
4. Successful Outcomes of Pivotal Clinical Trials and Regulatory Approvals: A primary driver of future revenue growth hinges on the successful execution and positive outcomes of the ongoing pivotal clinical trials for both AVIM Therapy (BACKBEAT study) and Virtue SAB (Virtue Trial). Favorable results from these trials are essential for obtaining regulatory approvals from bodies like the FDA, which will enable the company and its partners to market and sell these high-impact therapies in large, established global procedure markets.

Share Issuance

• In August 2025, Orchestra BioMed raised approximately $40 million in gross proceeds from a public follow-on offering of 9,413,367 shares of common stock and pre-funded warrants to purchase up to 5,136,363 shares, priced at $2.75 per share.
• As part of strategic transactions in August 2025, Medtronic invested $11.2 million and Ligand invested $5 million in private placements of common stock, contributing to total gross proceeds of $56.2 million from equity offerings including the public offering.
• The number of outstanding shares increased by 48.5% in the past year, indicating substantial dilution.

Inbound Investments

• In the second half of 2025, Orchestra BioMed secured nearly $150 million in new capital and capital commitments through strategic transactions, including partnerships with Medtronic, Ligand, and Terumo.
• In July 2025, Orchestra BioMed secured $70 million in new capital from Ligand Pharmaceuticals and Medtronic. Ligand committed $35 million in exchange for a tiered royalty on future sales and a $5 million equity investment, while Medtronic committed $20 million via a convertible promissory note and $10 million for shares in an equity private placement.
• Terumo invested an additional $20.0 million in Orchestra BioMed through a new series of non-voting convertible preferred stock, convertible into common stock at a minimum of $12 per share.

Outbound Investments

• Orchestra BioMed is expected to receive up to $21 million in total proceeds in connection with the acquisition of Vivasure Medical, a former strategic holding of Orchestra BioMed, by Haemonetics.

Capital Expenditures

• Capital expenditures for Orchestra BioMed Holdings, Inc. were -$489.0 thousand in 2025, representing a 69.2% year-over-year decrease.
• Net cash used in operating activities and for the purchase of fixed assets (excluding certain payments) was $66.9 million in 2025, primarily driven by increased cash outflows for research and development and clinical trial activities.
• Research and development expenses significantly increased by 36% to $58.2 million in 2025, primarily due to the ongoing BACKBEAT global pivotal study and the Virtue SAB program.